Treating Oligometastatic Prostate Cancer with Stereotactic Body Radiation Therapy

When it comes to treating oligometastatic prostate cancer, evidence shows that stereotactic body radiation therapy (SBRT), which is a form of high-precision cancer therapy that delivers substantially higher doses of radiation to the tumor site in just one or a few treatment sessions, is an excellent treatment option for men battling the disease.

An active clinical trial of targeted, high-dose radiation for men with oligometastatic prostate cancer shows SBRT treatment to be an effective and safe option for patients who wish to delay hormone-suppression therapy.  The phase II trial found that radiation therapy can generate an immune system response not previously believed possible in this type of cancer.

For the trial, 54 patients whose cancer had spread to a limited number of sites outside the prostate after treatment with surgery or radiation were placed in one of two categories:  those who were observed but received no further treatment for six months, and those who were treated with SBRT.  Men treated with SBRT were significantly less likely to experience increases in their PSA levels and lived significantly longer without any detectable disease progression than patients who received no additional treatment.  Also, six months later, just 19% of patients treated with SBRT saw their disease progress, compared to 61% of those that were just observed.

The results are good news because previous research has shown high-dose radiation to be safe and effective for men with localized or non-metastatic prostate cancer, but patients with oligometastatic disease, whose cancer has been treated but then returned to other parts of the body, generally have been considered incurable.

At Rush Radiosurgery, men diagnosed with oligometastatic prostate cancer are treated with SBRT with the TrueBeam™ STx system.  TrueBeam is a non-invasive prostate cancer treatment technology in which high-dose radiation is delivered to the tumor from a linear accelerator rotating around the body.  Hundreds of angles and beamwidth adjustments in the TrueBeam prescribed treatment plan enable the radiation to be contoured to the shape of the prostate.  This results in treatment aimed directly at the prostate gland, avoiding nearby critical anatomy.  This precision reduces treatment time to just five outpatient visits.  In comparison, conventional radiation therapy could require up to 45 visits.

To learn more about how Rush Radiosurgery treats oligometastatic diseases, including oligometastatic prostate cancer, please click here.